Compared with wild-type BRCA genotype patients, patients with advanced-stage ovarian cancer and BRCA1/2 mutations have been reported to have higher clinical response rates to platinum-based chemotherapy [10–12]. This evidence concerns the gene BRCA1 and ovarian cancer.